Stem cell therapy: a paradigm shift in reversing type 1 diabetes mellitus

Area of Science:

• Immunology
• Endocrinology
• Regenerative Medicine

Background:

• Type 1 diabetes mellitus (T1DM) is an autoimmune disease destroying pancreatic beta cells, requiring lifelong insulin therapy.
• Current T1DM treatments manage symptoms but do not address the underlying autoimmune cause or restore insulin production.
• Stem cell therapy presents a potential curative strategy by regenerating beta cells and modulating immune responses.

Purpose of the Study:

• To review various stem cell types for T1DM treatment.
• To explore mechanisms of action, including differentiation, immune protection, and gene editing.
• To assess current progress and challenges in stem cell therapy for T1DM.

Main Methods:

• Review of stem cell types: embryonic stem cells, induced pluripotent stem cells, mesenchymal stem cells, and pancreatic progenitor cells.
• Analysis of mechanisms: cell differentiation, immune evasion strategies (e.g., encapsulation), and gene editing.
• Evaluation of preclinical and clinical trial data.

Main Results:

• Early clinical trials show partial insulin independence in up to 40% of T1DM patients.
• Some participants experienced reduced exogenous insulin needs (20-30%) and increased C-peptide levels for 6-12 months.
• Stem cell therapy demonstrates potential for beta cell regeneration and immune modulation.

Conclusions:

• Stem cell therapy holds transformative potential for a functional cure in type 1 diabetes.
• Key challenges include scalable production, long-term graft survival, and achieving immune tolerance.
• Continued research is crucial to overcome existing barriers and advance T1DM treatment.